- 4848 Lemmon Avenue
- Suite 517
- Dallas, TX 75219
- Tel: (214) 905-5100
- Fax: (214) 905-5101
Access Pharmaceuticals is an emerging biopharmaceutical company specializing in products for cancer and supportive care. Access currently has one product that has been approved for marketing in China and S. Korea, and with marketing clearance in Europe and the U.S. The company also has three products in preclinical development. The company's products are based on Access' proprietary nanopolymer technologies which provide enhanced drug delivery options for both new and approved pharmaceutical active ingredients.
Access' primary focus is in oncology and cancer supportive care. Mucositis is a frequent side-effect of cancer therapy for which there is no established treatment. MuGard® is Access' proprietary nanopolymer formulation for the management of mucositis. This ready-to-use rinse provides a soothing oral coating.
Access recently announced a license agreement with AMAG Pharmaceuticals, Inc. related to the commercialization of MuGard® in the US and its territories. For more information on MuGard®, US visitors to this website should select the MuGard.com button, below. Non-US visitors should select the right-hand button:
For US residents
For non US-residents
Access is focusing its development effort on its Cobalamin technology. Cobalamin is Access' proprietary nanopolymer oral drug delivery technology. Using a 'Trojan Horse' approach, the technology uses the body's natural vitamin B12 uptake mechanism in the gut to transport drugs that otherwise would have little or no oral bioavailability. The company is currently developing products for the oral delivery of insulin and human growth hormone (HGH), and is collaborating with a number of companies to develop additional formulations of various other pharmaceutically-active compounds. Cells involved in certain diseases such as cancer often have an increased demand for vitamin B12 which results in a large increase in receptors for vitamin B12 on their surface. Another aspect of the Cobalamin technology therefore focuses on increasing the amount of drugs reaching sites of disease by making use of this higher receptor density. Application of the Cobalamin technology to enhance oral drug delivery has been named CobOral®, while application of the technology to target disease sites has been named CobaCyte®.